secwatch.observer — SEC 8-K summary
======================================

Issuer:     IO Biotech, Inc. (IOBTQ)
CIK:        0001865494
Form:       8-K
Filed at:   2024-05-14T23:59:59+00:00
Accession:  0001193125-24-137754
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IO Biotech Q1 2024 net loss $19.5M; Phase 3 melanoma interim ORR data expected Q3 2024
--------------------------------------------------------------------------------

- Net loss $19.5M for Q1 2024 vs $17.0M in Q1 2023; R&D expenses $14.3M (up from $11.9M).
- Cash and cash equivalents $118.0M at March 31, 2024; cash runway expected into Q4 2025.
- Phase 3 trial (IOB-013) of IO102-IO103 in advanced melanoma: interim ORR analysis expected Q3 2024; PFS analysis projected H1 2025.
- Completed Phase 2 basket trial (IOB-022) enrollment; Phase 2 basket trial (IOB-032) expanded with randomized melanoma cohort.
- Appointed Faiçal Miyara as Chief Business Officer and Marjan Shamsaei as SVP Commercial & Portfolio Lead.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1865494/000119312524137754/0001193125-24-137754-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1865494/000119312524137754/d799934d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-137754

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer